CRISPR Editing Tool Box Catalog No.:LI30010-2S E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide

4-tetrahydroquinolin-5-yl)methyl)amino)phenyl)propanoic acid

including JMJD isoforms

Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935)

311 nM and 39 nM for PI3Kα

CRISPR Editing Tool Box Catalog No.:LI30010-2S E)-N-(4-(3-chloro-4-fluorophenylamino)-7-(tetrahydrofuran-3-yloxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamideProduct Information A very useful small molecule collection to improve CRISPR editing efficacy, 2 mg solid each for the following compounds: SCR7: a NHEJ inhibitor promotes the efficiency of HDR 45 fold for CRISPR editing in both human and mouse cell lines. RS 1: a RAD51 Stimulatory compound enhances CRISPR Cas9 and TALEN mediated knock in efficiency. (Z) 4 Hydroxytamoxifen: a previously characterised as an Estrogen Receptor antagonist and now found